Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - The 2001-2008 National Health and Nutrition examination survey

Prostate

Volumn 74, Issue 5, 2014, Pages 561-567

  McDonald, Alicia C ^a,b   Vira, Manish A ^a   Vidal, Adriana C ^c   Gan, Wenqi ^a,b   Freedland, Stephen J ^c   Taioli, Emanuela ^a,b  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

NHANES; prostate cancer; screening; systemic inflammation

Indexed keywords

NHANES; PROSTATE CANCER; SCREENING; SYSTEMIC INFLAMMATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NUTRITION SURVEYS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC DISEASES; RISK;

EID: 84894234808     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22782     Document Type: Article

References (33)

1. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr., Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246.
2. Ploussard G, Nicolaiew N, Marchand C, Terry S, Allory Y, Vacherot F, Abbou CC, Salomon L, de la Taille A,. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: Longitudinal follow-up from a prospective trial. BJU Int 2013; 111: 988-996.
3. Kilpelainen TP, Tammela TL, Maattanen L, Kujala P, Stenman UH, Ala-Opas M, Murtola TJ, Auvinen A,. False-positive screening results in the Finnish prostate cancer screening trial. Br J Cancer 2010; 102: 469-474.
4. Hasui Y, Marutsuka K, Asada Y, Ide H, Nishi S, Osada Y,. Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate 1994; 25: 91-96. (Pubitemid 24246110)
5. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL,. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154: 407-413.
6. Okada K, Kojima M, Naya Y, Kamoi K, Yokoyama K, Takamatsu T, Miki T,. Correlation of histological inflammation in needle biopsy specimens with serum prostate- specific antigen levels in men with negative biopsy for prostate cancer. Urology 2000; 55: 892-898. (Pubitemid 30330795)
7. Karakiewicz PI, Benayoun S, Begin LR, Duclos A, Valiquette L, McCormack M, Bénard F, Saad F, Perrotte P,. Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. Int J Clin Pract 2007; 61: 425-430.
8. Wolters T, Roobol MJ, Schroder FH, van der Kwast TH, Roemeling S, van der Cruijsen-Koeter IW, Bangma CH, van Leenders GJ, ERSPC Rotterdam section. Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years ? BJU Int 2008; 101: 283-288.
9. Yli-Hemminki TH, Laurila M, Auvinen A, Maattanen L, Huhtala H, Tammela TL, Kujala PM,. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int 2013; 112: 735-741.
10. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG,. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269. (Pubitemid 46486616)
11. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-867. (Pubitemid 36019639)
12. Heikkila K, Ebrahim S, Lawlor DA,. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007; 61: 824-833.
13. dos Santos Silva I, De Stavola BL, Pizzi C, Meade TW,. Circulating levels of coagulation and inflammation markers and cancer risks: Individual participant analysis of data from three long-term cohorts. Int J Epidemiol 2010; 39: 699-709.
14. Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS,. Systemic inflammation and survival of patients with prostate cancer: Evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis 2012; 15: 195-201.
15. Guthrie GJK, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ,. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol 2013; 88: 218-230.
16. Roxburgh CSD, McMillan DC,. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2009; 6: 149-163.
17. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN,. ASCENT Investigators. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: Results from the ASCENT trial. Cancer 2008; 112: 2377-2383.
18. Buergy D, Wenz F, Groden C, Brockmann MA,. Tumor-platelet interaction in solid tumors. Int J Cancer 2012; 130: 2747-2760.
19. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, Kritchevsky SB,. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 2413-2418. (Pubitemid 41437845)
20. CDC/NCHS. National Health and Nutrition Examination Laboratory Protocol (C-Reactive Protein in Serum by Nephelometry). US Department of Health and Human Services, Centers for Disease Control and Prevention; Available from: http://www.cdc.gov/nchs/data/nhanes/nhanes-01-02/l11-b-met-c-reactive-protein. pdf
21. CDC/NCHS. National Health and Nutrition Examination Laboratory Protocol (Fibrinogen in Plasma by Rate of Clot Formation on the STA-Compact). US Department of Health and Human Services, Centers for Disease Control and Prevention; Available from: http://www.cdc.gov/nchs/data/nhanes/nhanes-01-02/ l11-b-met-fibrinogen.pdf
22. CDC/NCHS. National Health and Nutrition Examination Laboratory Protocol (Plasma Glucose). US Department of Health and Human Services, Centers for Disease Control and Prevention; Available from: http://www.cdc.gov/nchs/data/ nhanes/nhanes-01-02/l25-b-met-complete-blood-count.pdf
23. CDC/NCHS. National Health and Nutrition Examination Laboratory Protocol (Hybritech Prostate Specific Antigen [PSA] on Beckman Access). US Department of Health and Human Services, Centers for Disease Control and Prevention; Available from: http://www.cdc.gov/nchs/data/nhanes/nhanes-01-02/l11psa-b-met-total-psa. pdf
24. Lippi G, Montagnana M, Guidi GC,. Epidemiological association between C-reactive protein and prostate-specific antigen. Cancer 2009; 115 (5): 1132. doi: 10.1002/cncr.24116
25. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y,. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013; 58: 58-64.
26. Kantola T, Klintrup K, Vayrynen JP, Vornanen J, Bloigu R, Karhu T, Herzig KH, Näpänkangas J, Mäkelä J, Karttunen TJ, Tuomisto A, Mäkinen MJ,. Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer 2012; 107: 1729-1736.
27. Qiu J, Yu Y, Fu Y, Ye F, Xie X, Lu W,. Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 2012; 38: 651-657.
28. Lu DY, Chen XL, Cao JY, Li Z, Xue HW, Luo LJ, Xu B,. Effects of cancer chemotherapy on the blood fibrinogen concentrations of cancer patients. J Int Med Res 2000; 28: 313-317. (Pubitemid 32014298)
29. Everett CJ, Wells BJ, Frithsen IL, Koopman RJ,. Smoking, fibrinogen and cancer mortality. J Natl Med Assoc 2007; 99: 328-333. (Pubitemid 46608857)
30. Toriola AT, Laukkanen JA, Kurl S, Nyyssönen K, Ronkainen K, Kauhanen J,. Prediagnostic circulating markers of inflammation and risk of prostate cancer. Int J Cancer 2013; 133: 2961-2967.
31. St Sauver JL, Sarma AV, Jacobson DJ, McGree ME, Lieber MM, Girman CJ, Nehra A, Jacobsen SJ,. Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol 2009; 169: 1281-1290.
32. Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, Méjean C, Latino-Martel P, Hercberg S, Galan P, Czernichow S,. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: A nested case-control study. Am J Epidemiol 2013; 177: 3-13.
33. Stark JR, Li H, Kraft P, Kurth T, Giovannucci EL, Stampfer MJ, Ma J, Mucci LA,. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 2009; 124: 2683-2689.